XML 36 R6.htm IDEA: XBRL DOCUMENT v2.4.0.8
Consolidated Statements of Cash Flows (USD $)
In Thousands, unless otherwise specified
 6 Months Ended
Jun. 30, 2014
Jun. 30, 2013
Cash Flows from Operating Activities    
Net income (loss) $ 3,949 $ (14,152)
Adjustments to reconcile net income (loss) to net cash from operating activities:    
Depreciation and amortization 11,600 7,985
Deferred income taxes (2,675) (10,571)
Non-cash equity-based compensation 9,813 6,292
Provision (recovery) for bad debt (1,936) 11
Gross profit from sales of lab tools (2,435)  
Change in contingent consideration (29,368)  
Excess tax benefits from equity-based compensation   (461)
Other, net   15
Changes in operating assets and liabilities:    
Accounts receivable (32,721) 18,099
Inventories 12,052 (4,211)
Prepaid expenses and other current assets (6,621) (8,901)
Accounts payable (8,026) 20,912
Accrued expenses, customer deposits, deferred revenue and other current liabilities 29,638 (7,095)
Income taxes payable 646 (1,708)
Other, net (692) 7,536
Net cash provided by (used in) operating activities (16,776) 13,751
Cash Flows from Investing Activities    
Capital expenditures (4,509) (5,999)
Proceeds from the liquidation of short-term investments 121,233 272,449
Payments for purchases of short-term investments (92,029) (420,767)
Proceeds from sale of lab tools 7,034  
Other (685) (718)
Net cash provided by (used in) investing activities 31,044 (155,035)
Cash Flows from Financing Activities    
Proceeds from stock option exercises 9,125 313
Restricted stock tax withholdings (1,867) (2,335)
Excess tax benefits from equity-based compensation   461
Repayments of long-term debt (141) (132)
Net cash provided by (used in) financing activities 7,117 (1,693)
Effect of exchange rate changes on cash and cash equivalents 148 (32)
Net increase (decrease) in cash and cash equivalents 21,533 (143,009)
Cash and cash equivalents as of beginning of period 210,799 384,557
Cash and cash equivalents as of end of period $ 232,332 $ 241,548